Nasdaq

Exact Sciences price target raised to $70 from $60 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
Nasdaq

180 Life Sciences prices $2.9M registered direct offering at $2.41 per share

180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...
Yahoo Finance

Is Exact Sciences (EXAS) Pricing Reflect Long Term Cancer Screening Growth Potential

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. If you are trying to figure out whether Exact Sciences is ...
Business Insider

Exact Sciences price target lowered to $65 from $82 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...